Chemoimmunotherapy Improves Pathologic Outcomes in Gastroesophageal Carcinoma
(MedPage Today) -- Adding immunotherapy to neoadjuvant chemotherapy for resectable gastroesophageal cancer led to higher rates of disease downstaging and pathologic complete response (pCR), an exploratory analysis of a randomized trial showed... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - November 24, 2023 Category: Gastroenterology Source Type: news
Reprogramming Tumors; Bad Stool Samples; Human Experiences in Cancer Care
(MedPage Today) -- A novel treatment that reprograms tumors to make them more responsive to immunotherapy showed promising activity in a preliminary clinical study of triple-negative breast cancer. (Roswell Park Comprehensive Cancer Center, Journal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 18, 2023 Category: Hematology Source Type: news
Certain NSCLC Subgroups May Not Benefit From Immunotherapy Certain NSCLC Subgroups May Not Benefit From Immunotherapy
A comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 16, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Icahn School of Medicine at Mount Sinai Secures $5 Million NIH Grant for Cutting-Edge Cancer Target Discovery and Development Center
The Department of Immunology and Immunotherapy and the Icahn Genomics Institute (IGI) at the Icahn School of Medicine at Mount Sinai have been awarded a $5 million grant from the National Cancer Institute (NCI) of the National Institutes of Health to establish a state-of-the-art center... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 15, 2023 Category: Pharmaceuticals Tags: PDT Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Novel Toothpaste May Cut Peanut Allergy Risk for Adults Novel Toothpaste May Cut Peanut Allergy Risk for Adults
A phase 1 randomized, controlled trial tested the safety of a toothpaste that was specially formulated to be used as oral immunotherapy by adults with peanut allergy.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 13, 2023 Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Source Type: news
Benefits of Peanut Allergy Skin Patch for Toddlers Grow After First Year
(MedPage Today) -- ANAHEIM, Calif. -- Peanut-allergic toddlers who stayed on an investigational, epicutaneous immunotherapy skin patch reached higher levels of peanut tolerance during the second year, according to the open-label extension of... (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 13, 2023 Category: Allergy & Immunology Source Type: news
CT-based deep learning radiomics may help determine NSCLC treatment
Thursday, November 30 | 11:10 a.m.-11:20 a.m. | R4-SSCH10-2 | Room S405 A CT-based deep-learning radiomics biomarker appears to characterize the level of expression of programmed cell death ligand 1 (PD-L1) in non-small cell lung cancers (NSCLCs), according to study results that will be presented Thursday morning.The findings could help clinicians set treatment for lung cancer patients, since tumors that express 50% or greater levels of PD-L1 tend to respond well to immunotherapy, wrote a team led by Jingshan Gong, MD, of Shenzhen Second People's Hospital in China.The study included 259 patients with pathology-confirmed ...
Source: AuntMinnie.com Headlines - November 13, 2023 Category: Radiology Authors: Kate Madden Yee Tags: 2023 CT Preview Source Type: news
Immunotherapies Show No Increase in Cancer Recurrence Risk Immunotherapies Show No Increase in Cancer Recurrence Risk
Patients with immune-mediated diseases and a history of malignancy had similar rates of cancer recurrence whether or not they were receiving immunosuppressive treatments.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 11, 2023 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
TLS in Tumors May Predict Immunotherapy Benefit in NSCLC TLS in Tumors May Predict Immunotherapy Benefit in NSCLC
New data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 10, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Key Updates in Ovarian Cancer From ESMO 2023 Key Updates in Ovarian Cancer From ESMO 2023
Highlights in ovarian cancer from ESMO 2023 include results on first-line use of a PARP inhibitor and on the addition of immunotherapy to platinum-based chemotherapy, and PARP inhibition after relapse.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2023 Category: Consumer Health News Tags: None ReCAP Source Type: news
Special Toothpaste Might Curb Peanut Allergy in Adults
THURSDAY, Nov. 9, 2023 – Researchers are testing a toothpaste that aims to let patients who are sensitive to peanuts and other foods simply brush their allergies away.Doctors already treat some food allergy patients with oral immunotherapy —... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 9, 2023 Category: General Medicine Source Type: news
Immunotherapy plus an investigational cancer drug improves anti-tumor effects
An investigational therapy for solid tumors could be especially effective when combined with immunotherapy to target a specific kind of cancer cell, a research team at Duke and Harvard have found.
Led by Lee Zou, Ph.D., chair of Duke’s Department of Pharmacology & Cancer Biology, the researchers focused on the way some cancer cells impede normal DNA repair to fuel tumor formation. This phenomenon is known as defective DNA mismatch repair. (Source: World Pharma News)
Source: World Pharma News - November 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
COM701 + nivolumab + BMS-986207 (anti-TIGIT) resulted in clinically meaningful durable partial responses> 16 months in platinum resistant ovarian cancer patients COM701 dual and triple combinations mediated clinical benefit in platinum resistant ovarian cancer patients, independent of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 6, 2023 Category: Pharmaceuticals Tags: TRI TDS Source Type: news
